Global Clinical Trials Market to Surge to $73.2 Billion by 2028, Driven by Demand for Specialized Testing Services and Outsourcing to CROs
February 09, 2024 07:40 ET
|
Research and Markets
Dublin, Feb. 09, 2024 (GLOBE NEWSWIRE) -- The "Global Clinical Trials Market by Phase (Phase I, II, III), Service Type (Laboratory, Analytical Testing, Patient Recruitment, Protocol Designing),...
World Edema Clinical Trials (Phase I, Phase II, Phase III, Phase IV) Market Size, Share & Trends Analysis Report 2023-2030
November 06, 2023 06:23 ET
|
Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Edema Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Participant (Pediatrics,...
GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders
July 05, 2023 08:33 ET
|
The Greater Cannabis Company, Inc.
BALTIMORE, July 05, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next...
Global SYK Inhibitors Market & Clinical Trials Outlook Report 2023-2028: Potential $300 Million Opportunity, 1 Marketed Drug, Current & Forecast Sales, Competitive Landscape
May 24, 2023 06:08 ET
|
Research and Markets
Dublin, May 24, 2023 (GLOBE NEWSWIRE) -- The "Global SYK Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. This report contains a...
AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
April 05, 2023 08:00 ET
|
AI Therapeutics, Inc.
Significant reduction of toxic protein aggregate, Poly(GP) Significant increase in biomarker of target engagement, sGPNMB AIT-101 and active metabolites crossed the blood-brain barrier ...
Outlook on the SYK Inhibitors Global Market to 2028 - Players Include Calithera Biosciences, CrystalGenomics, CSPC Ouyi Pharmaceutical, Genosco and Hanmi Pharmaceutical
February 24, 2023 05:18 ET
|
Research and Markets
Dublin, Feb. 24, 2023 (GLOBE NEWSWIRE) -- The "Global SYK Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. This report contains a...
Global Clinical Trial Kits Market (2022 to 2030) - Featuring Almac, Alpha Laboratories and Brooks Life Science Among Others
September 09, 2022 07:03 ET
|
Research and Markets
Dublin, Sept. 09, 2022 (GLOBE NEWSWIRE) -- The "Clinical Trial Kits Market Share, Size, Trends, Industry Analysis Report, By Service , By Phase , By Region; Segment Forecast, 2022 - 2030" report has...
Global TIM3 Inhibitors Drug Clinical Trials & Market Opportunities Report 2022: Market to Surpass $1 Billion by 2028, Driven by the First Drug Approval Expected to be Launched by 2024
August 08, 2022 06:33 ET
|
Research and Markets
Dublin, Aug. 08, 2022 (GLOBE NEWSWIRE) -- The "TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global...
Global Clinical Trials Markets Report 2022: In 2020, IQVIA Dominated the Market, Followed by PPD, Syneos Health, PRA Health Sciences, and LabCorp - Forecast to 2026
March 28, 2022 04:13 ET
|
Research and Markets
Dublin, March 28, 2022 (GLOBE NEWSWIRE) -- The "Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy...
AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS
January 13, 2022 10:38 ET
|
AI Therapeutics, Inc.
GUILFORD, Conn., Jan. 13, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation...